Skip to main content
OpenTrials
Completed

NCT Number: NCT00947531

A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia

This clinical trial was performed to assess the clinical efficacy and safety of two 4 week treatment courses of daily intravenous administration of Cerebrolysin (20mL [milliliter] IV [intravenous] per day). The study was performed as prospective, randomised, double-blind, placebo-controlled, parallel group, multicentre study with 2 study groups.

Group 1: 20 mL Cerebrolysin and 100 mg (milligram) acetylsalicylic acid Group 2: Placebo (0.9% NaCl [sodium chloride]) and 100 mg acetylsalicylic acid The study drug was given once daily by intravenous infusion (20ml in 250ml saline solution) for 4 weeks on five consecutive days per week. This treatment regimen was repeated after a two-month treatment-free interval. Acetylsalicylic acid was given orally, once daily throughout the study duration of 24 weeks.

Altogether five clinical evaluation visits at Baseline (day 0) and at week 4, 12, 16, and 24 were necessary.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vascular Dementia Arterial Occlusive Diseases Arteriosclerosis Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Dementia Dementia, Vascular Intracranial Arterial Diseases Intracranial Arteriosclerosis Leukoencephalopathies Mental Disorders Nervous System Diseases Neurocognitive Disorders Vascular Diseases

Age range

50 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Chita State Medical Academy/Regional Psychiatric Hospital No. 2, Chita, Russia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men or post-menopausal women between 50 and 85 years
  • Clinical diagnosis of vascular dementia according to NINDS-AIREN criteria
  • CT or MRI results compatible with clinical diagnosis
  • MMSE score between 10 and 24, both inclusive
  • Modified Hachinski Ischemic Score >4
  • Hamilton Depression Scale score of less than or equal to 15
  • Adequate visual and auditory acuity to allow neuropsychological testing
  • Informed consent given by the patient and/or the next-of-kin

Exclusion criteria

  • Gastric ulcer associated with intolerance of acetylsalicylic acid treatment
  • Severe psychotic features, schizophrenia, depression, agitation or behavioral problems within the last three months that could lead to difficulty complying with the protocol
  • Any severe systemic illness or unstable medical condition that could lead to difficulty complying with the protocol or significantly limits life span.
  • Patients who in the investigator's opinion, would not comply with study procedures
  • Any significant neurological disease other than vascular dementia, such as Parkinson's disease, epilepsy, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, or multiple sclerosis
  • History of alcohol or substance abuse or dependence within the past two years
  • Patients with a history of systemic cancer within the past two years
  • Severe congestive heart failure or malignant, uncontrollable hypertension
  • Participation in a clinical trial with an investigational drug in the past four weeks

Treatment and study plan

Cerebrolysin

Drug

0.9% saline solution

Drug

Primary outcomes

  1. Change From Baseline in ADAS-cog+ (Alzheimer's Disease Assesment Scale - Cognitive Subpart) at Week 24

    Time frame: baseline and week 24

    The ADAS-COG+ is a psychometric instrument used to evaluate memory, attention, reasoning, language, orientation and praxis. The score ranges from 0 to 85 with 85 being the worst score. A negative change indicates cognitive improvement.

  2. CIBIC+ (Clinicians Interview-based Impression of Change) Score at Week 24

    Time frame: week 24

    This rating scale is based on the health care provider's "general clinical impressions" with the informant input (i.e. family members). It evaluates global function and is scored from 1 (marked improvement) to 7 (marked worsening).

Secondary outcomes

  1. Change From Baseline in ADAS-COG+ (Alzheimer's Disease Assessment Scale Cognitive Subpart)

    Time frame: week 4, 12, 16

    The modified Alzheimer's Disease Assessment Scale - Cognitive (ADAS-COG+) is a psychometric instrument used by a neuropsychologist that evaluates memory, attention, reasoning, language, orientation and praxis.

  2. ADAS-COG+ Response

    Time frame: week 4, 12, 16, 24

    A patient with an improvement from baseline of ≥ 4 points in the ADAS-COG+ score at a particular visit is considered to have an ADAS-COG+ response at that visit.

  3. Change From Baseline for Original ADAS-COG

    Time frame: week 4, 12, 16, 24

    The Original Alzheimer's Disease Assessment Scale - Cognitive (ADAS-COG) is comprised of items 1-11 of the modified ADAS-COG+.

  4. CIBIC+ Score

    Time frame: week 4, 12, 16

    The Clinician Interview-based Impression of Change (CIBIC+) score is assigned by an experienced physician familiar with the manifestations of dementia after interviewing the patient and the caregiver.

  5. CIBIC+ Response

    Time frame: week 4, 12, 16, 24

    A patient with a CIBIC+ score of 1 to 3 at a particular visit is considered to have a CIBIC+ response at that visit. Patients with a score of 0, indicating that the assessment was not performed, are considered to be non-responders.

  6. CIBIS+ (Clinicians Interview-Based Impression of Severity)

    Time frame: week 24

    The Clinician Interview-based Impression of Disease Severity (CIBIS+) score is assigned by an experienced physician, familiar with the manifestations of dementia, after interviewing the patient and the caregiver.

  7. Change From Baseline in MMSE (Mini-Mental State Examination) Score

    Time frame: week 4, 12, 16, 24

    The Mini-Mental State Examination (MMSE) is a frequently used screening instrument for clinical trials conducted in patients with Alzheimer's Disease. It evaluates orientation, registration, attention and calculation, recall and language.

  8. Change From Baseline in ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale)

    Time frame: week 4, 12, 16, 24

    The ADCS-ADL is a measure of functional disability. The ADCS-ADL assessment of activities of daily living is based on an interview with the caregiver.

  9. Change From Baseline in Trail-making Test

    Time frame: week 4, 12, 16, 24

    The Trail-making test is a frequently used instrument for the assessment of executive function.

  10. Change From Baseline in Clock-drawing Test

    Time frame: week 4, 12, 16, 24

    The Clock-drawing test is a frequently used screening instrument for dementia drug studies. It evaluates executive function of demented patients.

  11. Combined Response, i.e. Response in ADAS-COG+ and CIBIC+

    Time frame: week 4, 12, 16, 24

Sponsors and collaborators

Lead sponsor

Ever Neuro Pharma GmbH

Industry

Collaborators

  • Geny Research Corp.
  • acromion GmbH

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia

Acronym: VascDem

Important dates

Study start
2006
Study completion
2007
First posted
Jul 28, 2009
Registry last updated
Feb 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.